What AI Companies Get Wrong About Curing Cancer
Physician-scientist Emilia Javorsky argues that curing cancer is limited more by biology’s complexity, data quality, and incentives than by intelligence, and explores realistic uses of AI in drug development, trials, and reducing medical bureaucracy.
Watch Episode Here
Listen to Episode Here
Show Notes
Emilia Javorsky is a physician-scientist and Director of the Futures Program at the Future of Life Institute.
She joins the podcast to discuss her newly published essay on AI and cancer. She challenges tech claims that superintelligence will cure cancer, explaining why biology’s complexity, poor data, and misaligned incentives are bigger bottlenecks than raw intelligence. The conversation covers realistic roles for AI in drug discovery, clinical trials, and cutting unnecessary medical bureaucracy.
You can read the full essay at: curecancer.ai
CHAPTERS:
(00:00) Episode Preview
(01:10) Introduction and essay motivation
(06:30) Intelligence vs data bottlenecks
(19:03) Cancer's complexity and heterogeneity
(29:05) Measurement, health, and homeostasis
(41:41) AI in drug development
(50:13) Regulation, FDA, and innovation
(01:02:58) Practical paths toward cures
PRODUCED BY:
SOCIAL LINKS:
Website: https://podcast.futureoflife.org
Twitter (FLI): https://x.com/FLI_org
Twitter (Gus): https://x.com/gusdocker
LinkedIn: https://www.linkedin.com/company/future-of-life-institute/
YouTube: https://www.youtube.com/channel/UC-rCCy3FQ-GItDimSR9lhzw/
Apple: https://geo.itunes.apple.com/us/podcast/id1170991978
Spotify: https://open.spotify.com/show/2Op1WO3gwVwCrYHg4eoGyP